Latest news with #Recursion
Business Wire
6 minutes ago
- Business
- Business Wire
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments. 'The second quarter marked a pivotal step forward as we advanced our lead program, RLYB116, into a confirmatory PK/PD study, which is an important milestone that reflects the strength of our science and the dedication of our team. Meanwhile, the strategic divestiture of a preclinical asset underscores our commitment to disciplined portfolio management, enabling us to sharpen our focus and strengthen the balance sheet as we continue to develop transformative therapies for patients and build long-term value for shareholders,' said Stephen Uden, M.D., Chief Executive Officer of Rallybio. 'With the RLYB116 confirmatory PK/PD study underway, we continue to look forward to the release of topline data from Cohort 1 and Cohort 2, expected in the third and fourth quarter of 2025, respectively.' Recent Business Highlights and Upcoming Milestones: Corporate Updates In July 2025, Rallybio announced that it entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia (HPP), to its joint venture partner Recursion Pharmaceuticals (Recursion) for up to $25.0 million, including an upfront equity payment of $7.5 million and near-term milestones. The upfront payment extends Rallybio's cash runway into the middle of 2027. In addition to the upfront payment, Rallybio is eligible to receive a contingent equity payment of $12.5 million upon the initiation of additional preclinical studies, and a $5.0 million cash milestone payment in connection with the initiation of dosing in a Phase 1 clinical study, as defined in the agreement. Rallybio is also eligible to receive low single-digit royalties on all future net sales by Recursion of products comprising or incorporating certain compounds developed as part of the joint venture. In addition, Rallybio may be eligible to receive certain payments in the event of Recursion's sale of the REV102 program. RLYB116 Program Rallybio announced the initiation of dosing in the RLYB116 confirmatory clinical pharmacokinetic/pharmacodynamic (PK/PD) study in June 2025. Results from Cohort 1 and Cohort 2 are anticipated in the third and fourth quarter of 2025, respectively. Data from this study are expected to demonstrate complete and sustained complement inhibition as well as improved tolerability of RLYB116. In June 2025, Rallybio also announced that the initial indication focus for RLYB116 will be on two hematologic conditions with significant unmet need: immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB332 Program Rallybio continues to evaluate plans for future development of RLYB332, a long-acting, monoclonal anti-matriptase-2 antibody that has the potential to be a best-in-class treatment for diseases of iron overload. Preclinical data has demonstrated superior impact on PD parameters relative to comparator molecules, including serum iron, unsaturated iron binding capacity (UIBC), and transferrin saturation (TSAT). RLYB212 Program In April 2025, Rallybio announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The Company's decision to discontinue RLYB212 development was based on PK data from the Phase 2 clinical trial demonstrating the inability of the RLYB212 dose regimen to achieve predicted target concentrations, as well as the minimum target concentration required for efficacy. Safety follow-up of the sentinel participant in the Phase 2 trial will continue as specified in the clinical trial protocol. Second Quarter 2025 Financial Results Revenue: Revenue was $0.2 million for the second quarter of 2025, compared to $0.3 million for the same period in 2024. The decrease in revenue for the second quarter of 2025 was related to the collaboration agreement with Johnson & Johnson in the second quarter of 2024 and the recognition of revenue related to the collaboration's performance obligations. Research & Development (R&D) Expenses: R&D expenses were $6.1 million for the second quarter of 2025, compared to $12.9 million for the same period in 2024. The decrease in R&D expenses was primarily due to a decrease in development costs related to RLYB212, RLYB116 and other program candidates; offset by an increase related to payroll and personnel-related costs, largely related to the Company's workforce reduction announced in May 2025. General & Administrative (G&A) Expenses: G&A expenses were $4.2 million for the second quarter of 2025, compared to $4.4 million for the same period in 2024. The decrease in G&A expenses was primarily due to a decrease in professional fees and other general and administrative expenses; offset by an increase related to payroll and personnel-related costs, largely related to the 2025 workforce reduction. Net Loss and Net Loss Per Common Share: Rallybio reported a net loss of $9.7 million, or $0.22 per common share, for the second quarter of 2025 compared to a net loss of $16.2 million, or $0.37 per common share, for the same period in 2024. Cash Position: As of June 30, 2025, cash, cash equivalents, and marketable securities were $45.7 million. Rallybio expects these funds, together with the upfront payment received from the sale of REV102 to Recursion in July 2025, will be sufficient to support operations into the middle of 2027. About Rallybio Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology. The Company's lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements that are based on our management's beliefs and assumptions and currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the timing of data for the RLYB116 confirmatory PK/PD study, including data for Cohorts 1 and 2, whether the PK/PD confirmatory study will demonstrate improved tolerability and complete and sustained complement inhibition, the potential commercial opportunity for RLYB116, the Company's eligibility for certain future payments in connection with the Company's sale to Recursion of the REV102 program, and the Company's cash runway. The forward-looking statements in this press release are only predictions and are based largely on management's current expectations and projections about future events and financial trends that management believes may affect Rallybio's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully conduct our clinical trials, including the RLYB116 PK/PD confirmatory study, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio's filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio's Quarterly Report on Form 10-Q for the period ended March 31, 2025, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise. Condensed Consolidated Balance Sheets (Unaudited) (in thousands) JUNE 30, 2025 DECEMBER 31, 2024 Cash, cash equivalents and marketable securities $ 45,749 $ 65,511 Total assets 51,003 68,108 Total liabilities 5,039 6,454 Total stockholders' equity 45,964 61,654 Expand
Yahoo
a day ago
- Business
- Yahoo
Recursion Sets $100 Million Partnership Goal by 202
Recursion (NASDAQ:RXRX) just laid out a roadmap that balances science and cash, and it looks promising. CEO Christopher Gibson talked up how the Exscientia tech and the Boltz-2 partnership with MIT and Nvidia have supercharged their end-to-end platformfrom pinpointing targets to simulating trials. That boost in efficiency shines through in their finances. Warning! GuruFocus has detected 6 Warning Signs with RXRX. CFO Ben Taylor confirmed they finished Q2 with $533 M in the bank and expect to keep burn under $390 M next year. Even better, they're targeting over $100 M in partnership inflows by the end of 2026, which should carry them all the way through Q4 2027 without needing extra financing. On the science side, six internal programs are nearing key milestones. Oncology dose-escalation data should roll in by year-end and rare-disease updates are due early next year. The ClinTech AI platform now promises roughly 50 % faster enrollment projections, and they've hit a fourth Sanofi milestone while rolling out neuronal phenomaps with Roche and Genentech. This article first appeared on GuruFocus.
Yahoo
5 days ago
- Business
- Yahoo
Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month
Recursion Pharmaceuticals experienced a price increase of 9% over the past month, positioning it against the backdrop of a broader market decline driven by geopolitical tensions and weak jobs data. Despite these broader market headwinds, which saw significant tech stock declines due to tariff concerns and disappointing economic indicators, Recursion managed to outperform. The company's stock movement appeared isolated from these wider trends, which implies internal factors or developments might have played a part, although specific catalysts weren't highlighted during this period. This performance is noteworthy given the current market's overall downward trend of 2.7%. We've identified 3 possible red flags for Recursion Pharmaceuticals (1 is potentially serious) that you should be aware of. AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Recursion Pharmaceuticals' recent 9% monthly share price increase amidst broader market declines may suggest that internal developments, rather than external factors, are influencing investor sentiment. Over the past year, however, the company's total shareholder return was a decline of 19.09%, highlighting a contrast to the short-term positive movement. Comparatively, RXRX underperformed the US Biotechs industry, which saw an 8.4% decline over the same period, and also lagged behind the US market return of 17.7%. The heightened interest in the stock could be linked to enthusiasm around its AI-driven drug discovery programs, including REC-617 and REC-994 trials, which suggest potential future revenue growth. Yet, Recursion's lack of profitability and reliance on successful trial outcomes may introduce uncertainty into earnings forecasts. The company's expected revenue growth of 39.9% annually for the next three years could be influenced by the new developments and partnerships, possibly providing support to the optimistic forecasts. The current share price of US$5.68 remains below the consensus analyst price target of US$7.14, indicating a potential upside of 25.7%. This price target reflects expectations of significant future revenue and earnings improvements. However, analysts' forecasts include assumptions such as increased profit margins and successful translation of ongoing projects into commercial revenues, underscoring the importance of navigating the risks and uncertainties outlined in their analysis. Investors may need to weigh these factors carefully when considering the company's ability to meet future targets. Evaluate Recursion Pharmaceuticals' prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include RXRX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Daily Mail
24-07-2025
- Entertainment
- Daily Mail
Which King would Holly Jackson take to a desert island?
What Book... ... are you reading now? Blake Crouch's Recursion. I haven't read a huge amount this year as I've been so busy writing season two of the TV series of A Good Girl's Guide To Murder. When reading for 'fun', I like to have a break from crime thrillers as they feel too close to work, so sci-fi is what I reach for. I'm enjoying Recursion and its very unique take on time travel. ... would you take to a desert island? For nostalgia reasons, but also for practical reasons as it's very, very long, I'm going to say The Stand by Stephen King – the uncut version so that we can get all that extra material in and keep me entertained in my solitude (or if I need any extra pages to light a campfire). I first read it when I was around 14 years old, which was vastly inappropriate but I loved it. I re-read it again recently – it's the apocalyptic book that keeps on giving. He's truly the King for a reason. ... first gave you the reading bug? I think the first time I truly fell in love with reading was with a series of books called The Edge Chronicles, written by Paul Stewart and illustrated by Chris Riddell. And it wasn't just one series: it's a vast universe of connected trilogies, full of fantasy and adventure. It kept me very busy and entertained as a kid. And just to cheat slightly, something else which gave me the reading bug, but wasn't a book at all, was a 1994 movie called The Pagemaster – in which a boy becomes trapped in a library and is thrown into the different worlds of classic literature. I would rewatch it over and over again, and it truly pushed me towards books and the adventures they can take you on. ... left you cold? I'm going to take this question very literally and answer with Thin Air by Michelle Paver. It takes place up a mountain in the Himalayas, so it is a very, very cold book due to its setting. And in addition to the environmental kind, you might also shiver with fear, as it's a creepy ghost story. I thoroughly enjoyed it, so the colder the better I say.
Yahoo
08-07-2025
- Business
- Yahoo
Here's Why Shares in Recursion Pharmaceuticals Surged Today
Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. The deal de-risks the company's pipeline by removing uncertainty; however, there's still a long way to go before REV102 is commercialized. 10 stocks we like better than Recursion Pharmaceuticals › Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline. The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (NASDAQ: RLYB). REV102 is being developed to treat hypophosphatasia (HPP) -- a rare and debilitating genetic disorder that affects bone development. According to Recursion, "HPP is a devastating genetic disorder affecting over 7,800 diagnosed patients across the U.S. and major European countries." It targets an enzyme, ENPP1, whose inhibition is believed to help treat HPP. Until today, Recursion and Rallybio have had a joint venture to develop ENPP1 inhibitors, which have resulted in REV102, still in the preclinical stage of development. The deal is good news for both companies. Focusing on Rallybio, the company will receive: Some much-needed cash in the form of $7.5 million in up-front equity An equity payment of $12.5 million if REV102 undertakes additional preclinical trials A $5 million milestone payment after initiation of dosing in a phase 1 study Low-single-digit royalties on future sales of REV102 Meanwhile, Recursion gains full ownership of REV102 and can now develop the drug without worrying about Rallybio's consideration of the matter. The agreement helps de-risk the development of REV102 and removes uncertainty around it in connection with Rallybio's financial condition. That's a plus and adds value to Recursion's pipeline, even if REV102 is in a very early stage of development. Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Recursion Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $695,481!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $969,935!* Now, it's worth noting Stock Advisor's total average return is 1,053% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Here's Why Shares in Recursion Pharmaceuticals Surged Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
